Center for Cancer Experimental Therapeutics

癌症实验治疗中心

• 批准号: 6988669
• 负责人: Gunda I. Georg
• 金额: $ 178.63万
• 依托单位: UNIVERSITY OF KANSAS LAWRENCE
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-30 至 2010-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6988669
• 关键词: antineoplastics; drug discovery /isolation; neoplasm /cancer pharmacology

DESCRIPTION (provided by applicant): The goal of this proposal is to continue and expand the existing "COBRE Center for Cancer Experimental Therapeutics." Four state institutions the University of Kansas-Lawrence (KU), the KU Medical Center (KUMC), Kansas State University (KSU), and Wichita State University (WSU), combine resources and faculty to establish a Center to mentor junior faculty in cancer-related research and to create novel infrastructure needed for experimentation at the interface between chemistry and biology. Funds are requested for the support of five projects. Project investigators are partnered with established, active, senior faculty who will serve as their mentors. In addition, the competitive First Award Program to enhance the competitiveness of future recruits, and a program for start-up enhancement packages will be established. Support from the University of Kansas and the Kansas Technology Enterprise Corporation (KTEC) together with NIH-COBRE funding will provide continued backing for two existing Core facilities and a new Core. Two COBRE Cores, Medicinal Chemistry and High Throughput Screening, started in the last granting period, will receive continued support. A new Core facility for the generation of transgenic and knock-out animals will be established. These Cores are needed to identify novel biological targets, and novel bioactive compounds, that will be useful basic biomedical research tools, and potential therapeutic agents. The Core facilities will be operated by an experienced group of investigators with expertise in the areas of medicinal and combinatorial chemistry, cell and molecular biology, biochemistry, cancer cell biology, pharmacology and the development of novel bioassays for compound and cellular target identification. The combination of expertise for the identification of novel drug targets, generation and analysis of novel compounds, together with that for the development of bioassays for screening, offers a unique opportunity for multidisciplinary research. At the end of the granting period, the Center will be the KU-Lawrence part of a new joint Cancer Center with KU-Lawrence and the KU Medical Center. The three COBRE Core laboratories will become University-supported research service laboratories.

描述（由申请人提供）： 该提案的目标是继续和扩大现有的“COBRE癌症实验治疗中心”。堪萨斯-劳伦斯大学（KU）、堪萨斯医学中心（KUMC）、堪萨斯州立大学（KSU）和威奇托州立大学（WSU）这四个州立机构联合收割机资源和教师建立了一个中心，指导癌症相关研究的初级教师，并在化学和生物学之间的界面上创建实验所需的新基础设施。要求为五个项目提供资金。项目调查人员与已建立的，活跃的，资深的教师谁将作为他们的导师合作。此外，还将设立竞争性的第一奖励计划，以提高未来新员工的竞争力，并设立一个启动增强包计划。来自堪萨斯大学和堪萨斯科技企业公司（KTEC）的支持以及NIH-COBRE的资金将为两个现有的核心设施和一个新的核心设施提供持续的支持。在上一个资助期开始的两个COBRE核心项目，药物化学和高通量筛选，将得到持续的支持。将建立一个新的核心设施，用于生产转基因和基因敲除动物。需要这些核心来鉴定新的生物靶标和新的生物活性化合物，这将是有用的基础生物医学研究工具和潜在的治疗剂。核心设施将由一组经验丰富的研究人员运营，他们在药物和组合化学、细胞和分子生物学、生物化学、癌细胞生物学、药理学以及开发用于化合物和细胞靶点鉴定的新型生物测定方面具有专业知识。鉴定新型药物靶点、生成和分析新型化合物的专业知识与开发用于筛选的生物测定法的专业知识相结合，为多学科研究提供了独特的机会。在资助期结束时，该中心将成为KU劳伦斯与KU劳伦斯和KU医疗中心新联合癌症中心的一部分。三个COBRE核心实验室将成为大学支持的研究服务实验室。